- Trials with a EudraCT protocol (85)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
85 result(s) found for: Stool sample.
Displaying page 3 of 5.
EudraCT Number: 2013-001540-60 | Sponsor Protocol Number: MULTIPAIN6-2013 | Start Date*: 2013-08-08 | |||||||||||
Sponsor Name:Mech-Sense, Aalborg University Hospital | |||||||||||||
Full Title: A novel approach to assess gastrointestinal adverse effects of opioids | |||||||||||||
Medical condition: Opioid-induced bowel dysfunction. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004366-18 | Sponsor Protocol Number: CNTO148UCO1001 | Start Date*: 2013-07-30 | |||||||||||
Sponsor Name:Janssen Biologics B.V. | |||||||||||||
Full Title: A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human anti-TNFα Antibody, in Pediatric Subjects with Moderately to Severely Active ... | |||||||||||||
Medical condition: Ulcerative Colitis in pediatric subjects | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) BE (Completed) DE (Completed) NL (Ongoing) DK (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004676-37 | Sponsor Protocol Number: GD3-170-302 | Start Date*: 2005-04-27 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A randomized, double-blind study of GT267-004 versus vancomycin, and GT267-004 versus metronidazole, in patients with C.difficile-associated diarrhea | |||||||||||||
Medical condition: C. difficile-associated diarrhea (CDAD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed) DK (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020484-20 | Sponsor Protocol Number: 20621-200 | Start Date*: 2011-07-05 | |||||||||||
Sponsor Name:ViroPharma Incorporated | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF VP 20621 FOR PREVENTION OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) IN AD... | |||||||||||||
Medical condition: Clostridium difficile infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004994-94 | Sponsor Protocol Number: 3415A-002 | Start Date*: 2011-12-21 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. difficile toxin B), and MK-... | |||||||||||||
Medical condition: Recurrence of Clostridium difficile infection (CDI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) ES (Completed) DE (Completed) CZ (Completed) FI (Completed) PL (Completed) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004907-69 | Sponsor Protocol Number: H-030-011 | Start Date*: 2008-11-25 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Inc. | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase II randomized, placebo-controlled, double-blind, dose ranging study of a Clostridium difficile toxoid vaccine (ACAM-CDIFF) in subjects with Clostridium difficile-associated infection(CDI) | ||||||||||||||||||||||||||||||||||||||
Medical condition: Recurrence of Clostridium difficile Infection (CDI) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000197-35 | Sponsor Protocol Number: IR-HP-14-01 | Start Date*: 2015-06-09 | ||||||||||||||||
Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI | ||||||||||||||||||
Full Title: insulin resistance, obesity and gastrointestinal bacteria | ||||||||||||||||||
Medical condition: Helicobacter pylori infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003048-21 | Sponsor Protocol Number: Uni-Köln-1667 | Start Date*: 2014-03-10 | |||||||||||||||||||||||||||||||
Sponsor Name:University of Cologne | |||||||||||||||||||||||||||||||||
Full Title: CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR) | |||||||||||||||||||||||||||||||||
Medical condition: Immunocompromised patients at high risk of bloodstream infections with colonizing bacteria. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001272-37 | Sponsor Protocol Number: 0173 | Start Date*: 2019-01-10 | |||||||||||
Sponsor Name:Theravance Biopharma Ireland Limited | |||||||||||||
Full Title: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Subjects with Moderate... | |||||||||||||
Medical condition: Moderately-to-Severely Active Crohn’s Disease (CD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) PT (Completed) ES (Prematurely Ended) HU (Prematurely Ended) BG (Completed) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Ongoing) GR (Completed) HR (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005081-22 | Sponsor Protocol Number: D5670C00022 | Start Date*: 2018-05-16 | |||||||||||
Sponsor Name:MedImmune Limited, a wholly owned subsidiary of AstraZeneca | |||||||||||||
Full Title: An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obes... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002598-22 | Sponsor Protocol Number: MK-3475-782 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined with Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782) | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003179-23 | Sponsor Protocol Number: GS-US-419-4015 | Start Date*: 2017-04-13 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD) | |||||||||||||
Medical condition: Small Bowel Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) PL (Completed) HU (Completed) FR (Completed) AT (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001169-28 | Sponsor Protocol Number: 13705201 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Centre Hospitalier de Toulouse | |||||||||||||
Full Title: Traitement précoce de patients pédiatriques présentant un syndrome hémolytique et urémique typique par l’anticorps monoclonal anti-C5 eculizumab : es... | |||||||||||||
Medical condition: Hemolytic and uremic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003635-10 | Sponsor Protocol Number: 2814 | Start Date*: 2018-05-23 |
Sponsor Name:University of Bristol | ||
Full Title: Immediate oral, immediate topical or delayed oral antibiotics for acute otitis media with discharge (the Runny Ear STudy: REST) | ||
Medical condition: Acute Otitis Media with discharge | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-010163-16 | Sponsor Protocol Number: 08/0285 | Start Date*: 2009-06-05 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: Bile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease | ||||||||||||||||||
Medical condition: Active Crohn's disease affecting the ileum | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000732-34 | Sponsor Protocol Number: ABOXY_2017 | Start Date*: 2017-06-21 | ||||||||||||||||||||||||||
Sponsor Name:Mech-Sense, Dept. Gastroenterology & Hepatology, Aalborg University Hospital | ||||||||||||||||||||||||||||
Full Title: Oral Controlled Release Formulations to Patients with Gastrointestinal Dysfunction – Is the Release of Drug and the Absorption Impaired? | ||||||||||||||||||||||||||||
Medical condition: Healthy (pain) and patients (pain). | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002494-48 | Sponsor Protocol Number: version 1.0, 02 May 2006 | Start Date*: 2006-09-27 | |||||||||||
Sponsor Name:University College London / University College London Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Sildenafil in Crohn’s disease: an open label pilot study of Sildenafil in 15 patients with active colonic Crohn’s disease | |||||||||||||
Medical condition: Active colonic Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003023-14 | Sponsor Protocol Number: CSUC-02/21 | Start Date*: 2021-09-02 | |||||||||||
Sponsor Name:InDex Pharmaceuticals AB | |||||||||||||
Full Title: Pharmacokinetics of Cobitolimod Enemas in Participants with active Ulcerative Colitis | |||||||||||||
Medical condition: Moderate to Severe Active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002811-16 | Sponsor Protocol Number: CA209-587 | Start Date*: 2017-01-10 |
Sponsor Name:Universitätsklinik für Dermatologie und Allergologie der Paracelsus medizinischen Privatuniversität Salzburg | ||
Full Title: Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin | ||
Medical condition: Locally Advanced/Metastatic Squamous Cell Carcinoma of the Skin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003011-97 | Sponsor Protocol Number: 69HCL20_0071 | Start Date*: 2020-12-14 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Fluconazole as a new therapeutic tool in hypercalciuric patients with increased 1,25(OH)2D levels. | |||||||||||||
Medical condition: Hypercalciuria | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
